Characterization of diabetic kidney disease in 235 patients: clinical and pathological insights with or without concurrent non-diabetic kidney disease

Table 5 Medications for DKD alone group and DKD + NDKD group treatment

	DKD(%)	DKD + NDKD(%)	χ²	P
RASi	60(41.96%)	93(42.86%)	0.024	0.878
SGLT2 Inhibitors	31(21.68%)	28(12.90%)	5.540	0.019*
Tripterygium Glycosides Tablets	27(18.88%)	25(11.52%)	4.258	0.039*
Diuretics	14(9.79%)	25(11.52%)	0.264	0.607
Glucocorticoids	0(0.00%)	26(11.98%)	19.147	< 0.001*
Microvascular Protective Agent	5(3.50%)	5(2.30%)	0.475	0.491
Hydroxychloroquine	0(0.00%)	1(0.46%)	0.658	0.417
Combined Preparations	2(1.40%)	4(1.84%)	0.100	0.751
Immunosuppressive Drugs	0(0.00%)	8(3.69%)	5.424	0.02*
Biologics	0(0.00%)	2(0.92%)	1.321	0.25
GLP-1 RA	4(2.80%)	0(0.00%)	6.213	0.013*

Note: The following medications were used in the treatment of kidney diseases in this study:
Renin-Angiotensin System Inhibitors (RASi): Valsartan, Losartan Potassium, Telmisartan, Irbesartan, Benazepril, Perindopril
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA): Liraglutide
Diuretics: Hydrochlorothiazide, Torsemide, Furosemide, Spironolactone
Microvascular Protective Agent: Calcium Dobesilate
Combined Preparations: Valsartan-Amlodipine, Sacubitril-Valsartan
Immunosuppressive Drugs: Cyclophosphamide, Tacrolimus
Biologics: Rituximab

ISSN: 1471-2369